17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics: Difference between revisions
(Created page with "__NOTOC__ {{17-beta-hydroxysteroid dehydrogenase deficiency}} {{CMG}} ==Overview== ==References== {{reflist|2}} {{WH}} {{WS}} Category:Disease [[Category:Endocrinology and...") |
Jose Loyola (talk | contribs) No edit summary |
||
| (12 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{17-beta-hydroxysteroid dehydrogenase deficiency}} | {{17-beta-hydroxysteroid dehydrogenase deficiency}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{Abdulkerim}} | ||
==Overview== | ==Overview== | ||
Although the precise [[incidence]] of 17βHSD-3 deficiency is unknown, a recent study from the [[Netherlands]] estimated the incidence around 1 in 147,000 [[newborns]], with a calculated heterozygote frequency of 1 in 135. | |||
==Epidemiology and Demographics== | |||
*In the [[Netherlands]], [[17-beta-hydroxysteroid dehydrogenase deficiency]] is estimated to occur 1:147.000 newborns. | |||
*17βHSD3 deficiency may show increased frequencies among [[populations]] with a high intermarriage rate such as in [[Gaza]], among whom [[intermarriage]] is frequent, the [[incidence]] is 1 in 200 to 300 people. | |||
* The incidence of 17betaHSD3 deficiency is 0.65 times the [[incidence]] of [[AIS]], which is thought to be the most frequent known cause of male [[pseudohermaphroditism]] without [[dysgenic]] [[gonads]].<ref>{{cite journal |author=Boehmer A et al |title=17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations |journal=J Clin Endocrinol Metab |volume=84 |issue=12 |pages=4713-21 |year=1999 |pmid=10599740}}</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
| Line 8: | Line 15: | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Endocrinology | [[Category:Endocrinology]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
Latest revision as of 07:45, 20 October 2022
|
17-beta-hydroxysteroid dehydrogenase deficiency Microchapters |
|
Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics |
|
FDA on 17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics |
|
CDC on 17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics |
|
17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics in the news |
|
Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency epidemiology and demographics |
|
Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]
Overview
Although the precise incidence of 17βHSD-3 deficiency is unknown, a recent study from the Netherlands estimated the incidence around 1 in 147,000 newborns, with a calculated heterozygote frequency of 1 in 135.
Epidemiology and Demographics
- In the Netherlands, 17-beta-hydroxysteroid dehydrogenase deficiency is estimated to occur 1:147.000 newborns.
- 17βHSD3 deficiency may show increased frequencies among populations with a high intermarriage rate such as in Gaza, among whom intermarriage is frequent, the incidence is 1 in 200 to 300 people.
- The incidence of 17betaHSD3 deficiency is 0.65 times the incidence of AIS, which is thought to be the most frequent known cause of male pseudohermaphroditism without dysgenic gonads.[1]